This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.

How to use REZISTOL

INSTRUCTIONS for medical use of the medicinal product NAPHTHYZIN^®(NAPHTHYZIN^®)

Composition

active substance: naphazoline; 1 ml of the preparation contains 0.5 mg or 1 mg of naphazoline nitrate; excipients: boric acid, purified water.

Pharmaceutical form

Nasal drops.

Main physical and chemical properties

Transparent, colorless or slightly yellowish liquid.

Pharmacotherapeutic group

Decongestants and other preparations for local use in diseases of the nasal cavity. Sympathomimetics. ATC code R01A A08.

Pharmacological properties

Pharmacodynamics

Naphthyzin^®has a pronounced vasoconstrictive effect on peripheral vessels due to its effect on α-adrenergic receptors. When applied to mucous membranes, it reduces swelling, hyperemia, exudation, which helps to relieve nasal breathing in rhinitis. Naphazoline helps to open and expand the outlet ducts of the paranasal sinuses and Eustachian tubes, which improves the outflow of secretions and prevents the settling of bacteria.

Pharmacokinetics

When used locally, naphazoline is completely absorbed.

The therapeutic effect occurs within 5 minutes and lasts for 4-6 hours when used intranasally.

Clinical characteristics

Indications

Acute rhinitis. As an auxiliary agent in the inflammation of the paranasal sinuses and middle ear.

To reduce swelling of the mucous membrane during diagnostic intervention.

Contraindications

Increased sensitivity to any components of the medicinal product.

Dry inflammation of the nasal mucosa.

Interaction with other medicinal products and other types of interactions

The use of Naphthyzin^®simultaneously with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, maprotiline, or within several days after their cancellation may cause an increase in arterial pressure.

Special instructions

The medicinal product should be used with great caution in severe cardiovascular diseases (arterial hypertension, ischemic heart disease), in diabetes, hyperthyroidism, pheochromocytoma, concomitant use of MAOIs or other products that may have a hypertensive effect. Caution is necessary during general anesthesia using anesthetics that increase the sensitivity of the myocardium to sympathomimetics (e.g., halothane), as well as in bronchial asthma.

When using high doses of the preparation, the development of such side effects from the cardiovascular and nervous systems as palpitations, arterial hypertension, arrhythmia, headache, dizziness, drowsiness, or insomnia is possible.

It is essential to avoid prolonged use and overdose, especially in children. Prolonged use of preparations intended to relieve swelling of the mucous membrane may lead to swelling and subsequent atrophy of the nasal mucosa.

Use during pregnancy or breastfeeding

There are no data on the ability of naphazoline to penetrate the placental barrier or into breast milk. Therefore, before prescribing the preparation to women during pregnancy or breastfeeding, it is necessary to carefully consider all possible risks and benefits of treatment and prescribe the medicinal product only if it is absolutely necessary.

Ability to affect the reaction rate when driving vehicles or other mechanisms

The use of the Naphthyzin^®medicinal product in recommended doses does not affect the ability to drive vehicles or mechanisms. When exceeding the recommended doses, dizziness and drowsiness are possible.

Method of use and doses

Naphthyzin^®is instilled into each nasal passage, tilting the head slightly back and to the right when instilling into the right nostril and to the left when instilling into the left nostril.

For therapeutic purposes. Adults and children over 15 years old - 1-3 drops of 0.05%-0.1% solution into each nasal passage.

Children aged 3-6 years are instilled with a 0.05% solution, 1-2 drops into each nasal passage;

children aged 6-15 years - 2 drops into each nasal passage.

Naphthyzin^®is used 3 times a day, but not more often than every 4 hours.

Naphthyzin^®should not be used for more than 5 days in adults and more than 3 days in children.

Naphthyzin^®can be used again only after a few days.

In case of nasal bleeding, use tampons moistened with a 0.05% solution of the preparation.

For diagnostic purposes (e.g., for the diagnosis and treatment of nasal polyps). After cleaning the nasal cavity, 3-4 drops of 0.05%-0.1% solution are instilled into each nasal passage or a tampon moistened in a 0.05%-0.1% solution is inserted for 2-3 minutes.

In case of swelling of the vocal cords, 1-2 ml of the preparation is injected with a laryngeal syringe.

Children

Children aged 3 to 15 years can use Naphthyzin^®0.05%.

Children over 15 years old can use Naphthyzin^®0.1%.

Overdose

Overdose or accidental ingestion of the preparation may cause systemic side effects: nervousness, increased sweating, headache, tremor, tachycardia, feeling of palpitations, arterial hypertension. Cyanosis, nausea, increased body temperature, spasms, cardiac arrest, pulmonary edema, mental disorders, pallor of the skin, heart attack may occur.

The suppressive effect on the central nervous system is manifested by such symptoms as decreased body temperature; bradycardia; increased sweating; drowsiness; shock-like hypotension; apnea; coma. The risk of overdose is higher in children, who are more susceptible to the negative effects than adults.

Treatment is symptomatic.

Side effects

When used in recommended doses, Naphthyzin^®is usually well-tolerated. In patients with increased sensitivity, the medicinal product may rarely cause burning and dryness of the nasal mucosa. In isolated cases, a feeling of severe nasal congestion may occur.

Only in isolated cases does a systemic side effect occur (most often with overdose):

from the immune system: allergic reactions, including Quincke's edema, burning;
from the nervous system: nervousness, headache, tremor;
from the cardiovascular system: tachycardia, palpitations;
from the vascular system: arterial hypertension;
from the skin and subcutaneous tissue: increased sweating.

Prolonged (more than 5 days for adults and more than 3 days for children) or frequent use of the medicinal product may lead to habituation, which is accompanied by intense swelling of the nasal mucosa, occurring after a relatively short period of time after use. Long-term use of the preparation may cause damage to the epithelium of the mucous membrane, suppression of the activity of the epithelial cilia, and cause irreversible damage to the mucous membrane and the development of dry rhinitis.

Shelf life

3 years.

After opening the bottle, the shelf life of the preparation is 28 days.

Do not use the preparation after the expiration date stated on the packaging.

Storage conditions

Store in the original packaging at a temperature not exceeding 25 °C. Store in a place inaccessible to children.

Packaging

10 ml in a glass bottle. 1 bottle in a pack.

Release category

Without a prescription.

Manufacturer

Pharmaceutical company "Pharmak".

Location of the manufacturer and its address

Ukraine, 04080, Kyiv, Kyrylivska street, 74.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
Evaluation of symptoms and guidance on further diagnostic testing
Preventive check-ups and regular health monitoring
Medical support during travel or after relocation
Treatment adjustments and lifestyle recommendations based on your personal history

Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.